Global Kidney Cancer Drug Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022
The global kidney cancer drug market is estimated to reach by USD 4.5 billion at a CAGR of 6.2% till 2022. Growing prevalence for lifestyle tempted diseases such as excessive drinking and smoking coupled with chronic diseases such as kidney cancer and tumor are some of the driving factors which are responsible for the growth of the market of kidney cancer drug. Increasing geriatric population is also contributing for the growth of the market as the people of this age group are more likely to suffer by chronic diseases. Additionally, these cancer drugs are long term treatment regiments which are available for patients who are at stage advanced metastatic tumor. Along with the driving factors the kidney cancer drug market also has the factors which are responsible for hampering the market growth such as increasing preference for geriatric drug among the consumers and high prices for branded drugs are some of the restraints which are negatively impacting the market growth of kidney cancer drug.
The global kidney cancer drug market is majorly segmented on the basis of type, on the basis of brand and on the basis of geography. Based upon the type the kidney cancer drug market is categorized in to clear cell, papillary (type 1 and type 2), chromophobe, oncocytic, and collecting duct. Based upon the brand the kidney cancer drug market is sub categorized in to nexavar (sorafenib), sutent (sunitinib), afinitor (Everolimus), votrient (pazopanib) , Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), and Proleukin (Aldesleukin).
Sutent (sunitinib) is a well-known cancer drug and more often used as the first line treatment of renal cell carcinoma (RCC) but due to the relatively high pricing of sunitinib drug has been proven a serious drawback for the use of sutent drug although it has been considered as the first line agent for the treatment for renal cell carcinoma (RCC). In terms of market growth the drug, votrient is estimated to have the highest growth rate among the entire kidney cancer drug during the coming years.
On the basis of the geography the kidney cancer drug market is mainly segmented into North America, Latin America, Europe, APAC and the rest of the world. North America holds the largest market share for kidney cancer drug globally. Rising prevalence of kidney cancer and kidney diseases are majorly impacting the marker growth in this region.
However, during the forecasted years Asia Pacific region is also expected to see the highest growth due to the rising patient awareness level and lower cost production of drugs and increase in patients who are suffering from renal diseases such as kidney cell carcinoma.
The kidney cancer drug market is dominated by some of the major key players such asF. Hoffmann-La Roche AG (Switzerland), Amgen (US),Onyx Pharmaceuticals Inc. (US), Bayer AG (Germany), Active Biotech AB (Sweden),GlaxoSmithKline plc (UK), Novartis AG (Switzerland) Genentech, Inc. (US), Cipla Limited (India), these are the key player who dominate the world market with 50% share of global kidney cancer drug market.
Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.